CVS Will Pay $37.8M To Settle Insulin Pen Overbilling Claims

By Mark Payne · December 2, 2025, 2:32 PM EST

CVS has agreed to pay $37.76 million to settle allegations that the major pharmacy retailer violated federal law by overdispensing and overbilling for insulin pens to government healthcare programs, federal prosecutors...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login